Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna. The agreement gives Merck ...
Fluorescent microscope image of the proximal tubule, the part of the kidney that’s most affected by ceramides. Credit image creator; use only for content related to this press release.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback